Takatani Setsuo, Sakamoto Tohru, Ohuchi Katsuhiro, Nakamura Makoto, Mizuno Tomohiro, Arai Hirokuni
Department of Artificial Organs, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Japan.
ASAIO J. 2002 Sep-Oct;48(5):538-45. doi: 10.1097/00002480-200209000-00017.
An ultracompact, one piece, totally implantable electromechanical total artificial heart (TAH) has been developed as a permanent replacement for failing hearts. It consists of left and right pusher plate blood pumps (stroke volume 55 ml) made of titanium alloy (Ti-6Al-7Nb) sandwiching a miniaturized electromechanical actuator between them. The diameter of the TAH is 90 mm, with a thickness of 70 mm, yielding an overall volume of 400 ml. It weighs 450 g. Although it is miniaturized, it provided a maximum pump output of 8 L/min against a left afterload of 100 mm Hg. It required approximately 12 watts to provide a pump output of 6.5 L/min with maximum efficiency of 13.5%. To balance left and right flow, the right stroke length was made 10% shorter than the left, and an auxiliary compliance chamber was used to compensate for additional flow differences between them. Motor commutation pulses and a Hall effect pusher plate sensor signal were used in the controller to implement the left master alternate variable rate mode. The calf fitting study revealed excellent anatomic compatibility, and the first successful survivor was obtained in December 2001. Studies of system endurance and biocompatibility are required to ensure long-term reliability. This TAH is promising for permanent replacement of the failing heart as well as for bridge to heart transplantation for the smaller size group of end-stage cardiac patients.
一种超紧凑型、一体式、完全可植入的机电式全人工心脏(TAH)已被开发出来,作为衰竭心脏的永久性替代品。它由左右推板血泵(每搏输出量55毫升)组成,血泵由钛合金(Ti-6Al-7Nb)制成,中间夹着一个小型化的机电致动器。TAH的直径为90毫米,厚度为70毫米,总体积为400毫升。它重450克。尽管它已小型化,但在100毫米汞柱的左心室后负荷下,其最大泵输出量为8升/分钟。在泵输出量为6.5升/分钟且最大效率为13.5%时,它需要约12瓦的功率。为了平衡左右血流量,右心室的冲程长度比左心室短10%,并使用一个辅助顺应性腔室来补偿它们之间额外的流量差异。控制器中使用电机换向脉冲和霍尔效应推板传感器信号来实现左主交替变速模式。小牛植入研究显示出极佳的解剖学兼容性,2001年12月获得了首例成功存活者。需要进行系统耐久性和生物相容性研究以确保长期可靠性。这种TAH对于衰竭心脏的永久性替代以及为较小体型的终末期心脏病患者进行心脏移植搭桥而言很有前景。